{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:37:41Z","timestamp":1790678261799,"version":"4.1.0"},"reference-count":104,"publisher":"American Diabetes Association","issue":"1","license":[{"start":{"date-parts":[[2020,12,21]],"date-time":"2020-12-21T00:00:00Z","timestamp":1608508800000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"<jats:p>Diabetes is the most frequent cause of chronic kidney disease (CKD), leading to nearly half of all cases of kidney failure requiring replacement therapy. The principal cause of death among patients with diabetes and CKD is cardiovascular disease (CVD). Sodium\/glucose cotransporter 2 (SGLT2) inhibitors were developed to lower blood glucose levels by inhibiting glucose reabsorption in the proximal tubule. In clinical trials designed to demonstrate the CVD safety of SGLT2 inhibitors in type 2 diabetes mellitus (T2DM), consistent reductions in risks for secondary kidney disease end points (albuminuria and a composite of serum creatinine doubling or 40% estimated glomerular filtration rate decline, kidney failure, or death), along with reductions in CVD events, were observed. In patients with CKD, the kidney and CVD benefits of canagliflozin were established by the CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) trial in patients with T2DM, urinary albumin-creatinine ratio &amp;gt;300 mg\/g, and estimated glomerular filtration rate of 30 to &amp;lt;90 mL\/min\/1.73 m2. To clarify and support the role of SGLT2 inhibitors for treatment of T2DM and CKD, the National Kidney Foundation convened a scientific workshop with an international panel of more than 80 experts. They discussed the current state of knowledge and unanswered questions in order to propose therapeutic approaches and delineate future research. SGLT2 inhibitors improve glomerular hemodynamic function and are thought to ameliorate other local and systemic mechanisms involved in the pathogenesis of CKD and CVD. SGLT2 inhibitors should be used when possible by people with T2DM to reduce risks for CKD and CVD in alignment with the clinical trial entry criteria. Important risks of SGLT2 inhibitors include euglycemic ketoacidosis, genital mycotic infections, and volume depletion. Careful consideration should be given to the balance of benefits and harms of SGLT2 inhibitors and risk mitigation strategies. Effective implementation strategies are needed to achieve widespread use of these life-saving medications.<\/jats:p>","DOI":"10.2337\/dbi20-0040","type":"journal-article","created":{"date-parts":[[2020,10,26]],"date-time":"2020-10-26T18:10:23Z","timestamp":1603735823000},"page":"1-16","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":98,"title":["SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation"],"prefix":"10.2337","volume":"70","clinical-trial-number":[{"clinical-trial-number":"nct03057951","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03619213","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03594110","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03036150","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Katherine R.","family":"Tuttle","sequence":"first","affiliation":[{"name":"Providence Health Care and University of Washington School of Medicine, Spokane, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4244-8335","authenticated-orcid":false,"suffix":"III","given":"Frank C.","family":"Brosius","sequence":"additional","affiliation":[{"name":"University of Arizona College of Medicine, Tucson, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Cavender","sequence":"additional","affiliation":[{"name":"University of North Carolina School of Medicine, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Fioretto","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Fowler","sequence":"additional","affiliation":[{"name":"The Voice of the Patient, Inc, Elmhurst, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiddo J.L.","family":"Heerspink","sequence":"additional","affiliation":[{"name":"University of Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Manley","sequence":"additional","affiliation":[{"name":"National Kidney Foundation, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren K.","family":"McGuire","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Molitch","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern, University Feinberg School of Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy K.","family":"Mottl","sequence":"additional","affiliation":[{"name":"University of North Carolina School of Medicine, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh","family":"Perreault","sequence":"additional","affiliation":[{"name":"University of Colorado Anschutz Medical Campus, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia E.","family":"Rosas","sequence":"additional","affiliation":[{"name":"Joslin Diabetes Center and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center Copenhagen, Gentofte, Denmark"},{"name":"University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Sola","sequence":"additional","affiliation":[{"name":"University of the Republic, Montevideo, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Vallon","sequence":"additional","affiliation":[{"name":"University of California-San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[{"name":"George Institute for Global Health, UNSW Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2020,10,26]]},"reference":[{"key":"2022031211205977700_B1","volume-title":"National Diabetes Statistics Report, 2020","author":"Centers for Disease Control and Prevention","year":"2020"},{"key":"2022031211205977700_B2","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Foundation","year":"2019","edition":"9th ed."},{"key":"2022031211205977700_B3","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI clinical practice guideline for diabetes and CKD: 2012 update","volume":"60","author":"National Kidney Foundation","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2022031211205977700_B4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1053\/j.ajkd.2011.09.017","article-title":"Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database","volume":"59","author":"Packham","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2022031211205977700_B5","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022031211205977700_B6","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart disease and stroke statistics-2017 update: a report from the American Heart Association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"key":"2022031211205977700_B7","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/CIR.0000000000000230","article-title":"Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association","volume":"132","author":"Fox","year":"2015","journal-title":"Circulation"},{"key":"2022031211205977700_B8","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2147\/DDDT.S50773","article-title":"Update on developments with SGLT2 inhibitors in the management of type 2 diabetes","volume":"8","author":"Nauck","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"2022031211205977700_B9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/1479164114561992","article-title":"Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences","volume":"12","author":"Gallo","year":"2015","journal-title":"Diab Vasc Dis Res"},{"key":"2022031211205977700_B10","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/jcpt.12077","article-title":"The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors","volume":"38","author":"Cangoz","year":"2013","journal-title":"J Clin Pharm Ther"},{"key":"2022031211205977700_B11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"2022031211205977700_B12","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2022031211205977700_B13","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2022031211205977700_B14","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2022031211205977700_B15","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1161\/CIRCULATIONAHA.119.044359","article-title":"Evaluating the effects of canagliflozin on cardiovascular and renal events in patients with type 2 diabetes mellitus and chronic kidney disease according to baseline HbA1c, including those with HbA1c &lt;7%: results from the CREDENCE Trial","volume":"141","author":"Cannon","year":"2020","journal-title":"Circulation"},{"key":"2022031211205977700_B16","article-title":"The Dapagliflozin in Heart Failure with Reduced Ejection Fraction Trial (DAPA-HF): outcomes in patients with CKD and effects on renal function","author":"McMurray","year":"2019"},{"key":"2022031211205977700_B17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.12.027","article-title":"Renoprotective effects of sodium-glucose cotransporter-2 inhibitors","volume":"94","author":"Heerspink","year":"2018","journal-title":"Kidney Int"},{"key":"2022031211205977700_B18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1053\/j.ajkd.2018.03.022","article-title":"SGLT2 inhibition for the prevention and treatment of diabetic kidney disease: a review","volume":"72","author":"Alicic","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"2022031211205977700_B19","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"2022031211205977700_B20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"key":"2022031211205977700_B21","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1681\/ASN.2016060666","article-title":"Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment","volume":"28","author":"Tonneijck","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2022031211205977700_B22","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41581-020-0256-y","article-title":"The tubular hypothesis of nephron filtration and diabetic kidney disease","volume":"16","author":"Vallon","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"2022031211205977700_B23","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"2022031211205977700_B24","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int"},{"key":"2022031211205977700_B25","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1046\/j.1523-1755.2001.00482.x","article-title":"Efferent arteriole tubuloglomerular feedback in the renal nephron","volume":"59","author":"Ren","year":"2001","journal-title":"Kidney Int"},{"key":"2022031211205977700_B26","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2337\/diab.43.5.629","article-title":"Increased renal metabolism in diabetes. Mechanism and functional implications","volume":"43","author":"K\u00f6rner","year":"1994","journal-title":"Diabetes"},{"key":"2022031211205977700_B27","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/dom.13620","article-title":"The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: a systematic review and meta-analysis","volume":"21","author":"Wang","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2022031211205977700_B28","doi-asserted-by":"crossref","first-page":"F969","DOI":"10.1152\/ajprenal.00551.2017","article-title":"SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism","volume":"314","author":"Layton","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022031211205977700_B29","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/ki.2008.350","article-title":"Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics","volume":"74","author":"Fine","year":"2008","journal-title":"Kidney Int"},{"key":"2022031211205977700_B30","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.ejrad.2011.03.045","article-title":"Noninvasive evaluation of renal oxygenation in diabetic nephropathy by BOLD-MRI","volume":"81","author":"Yin","year":"2012","journal-title":"Eur J Radiol"},{"key":"2022031211205977700_B31","doi-asserted-by":"crossref","first-page":"F1317","DOI":"10.1152\/ajprenal.00536.2012","article-title":"GC\/TOFMS analysis of metabolites in serum and urine reveals metabolic perturbation of TCA cycle in db\/db mice involved in diabetic nephropathy","volume":"304","author":"Li","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022031211205977700_B32","doi-asserted-by":"crossref","first-page":"e86976","DOI":"10.1172\/jci.insight.86976","article-title":"Tissue-specific metabolic reprogramming drives nutrient flux in diabetic complications","volume":"1","author":"Sas","year":"2016","journal-title":"JCI Insight"},{"key":"2022031211205977700_B33","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1681\/ASN.2013020126","article-title":"Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease","volume":"24","author":"Sharma","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2022031211205977700_B34","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"2022031211205977700_B35","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2022031211205977700_B36","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects","volume":"139","author":"Sano","year":"2019","journal-title":"Circulation"},{"key":"2022031211205977700_B37","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11886-019-1165-1","article-title":"Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure","volume":"21","author":"Scheen","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"2022031211205977700_B38","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/dom.13126","article-title":"Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis","volume":"20","author":"Hallow","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2022031211205977700_B39","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00125-016-4158-2","article-title":"The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -\/- mice fed a western diet","volume":"60","author":"Han","year":"2017","journal-title":"Diabetologia"},{"key":"2022031211205977700_B40","doi-asserted-by":"crossref","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice","volume":"306","author":"Vallon","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022031211205977700_B41","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/dom.13301","article-title":"Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers","volume":"20","author":"Dekkers","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2022031211205977700_B42","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia"},{"key":"2022031211205977700_B43","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2337\/dc11-1346","article-title":"Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function","volume":"35","author":"Zoppini","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031211205977700_B44","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/dom.13101","article-title":"Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials","volume":"20","author":"Zhao","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2022031211205977700_B45","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ahj.2018.08.016","article-title":"Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)","volume":"206","author":"Cannon","year":"2018","journal-title":"Am Heart J"},{"key":"2022031211205977700_B46","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"2022031211205977700_B47","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1475-2840-13-102","article-title":"Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME\u2122)","volume":"13","author":"Zinman","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"2022031211205977700_B48","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","article-title":"Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)","volume":"137","author":"Mahaffey","year":"2018","journal-title":"Circulation"},{"key":"2022031211205977700_B49","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/CIRCULATIONAHA.119.042007","article-title":"Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups","volume":"140","author":"Mahaffey","year":"2019","journal-title":"Circulation"},{"key":"2022031211205977700_B50","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","article-title":"Mortality and cardiovascular disease in type 1 and type 2 diabetes","volume":"376","author":"Rawshani","year":"2017","journal-title":"N Engl J Med"},{"key":"2022031211205977700_B51","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","article-title":"Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation"},{"key":"2022031211205977700_B52","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1161\/CIRCULATIONAHA.118.039177","article-title":"Empagliflozin and the risk of heart failure hospitalization in routine clinical care","volume":"139","author":"Patorno","year":"2019","journal-title":"Circulation"},{"key":"2022031211205977700_B53","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/CIRCULATIONAHA.114.014796","article-title":"Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the Reduction of Atherothrombosis for Continued Health (REACH) Registry","volume":"132","author":"Cavender","year":"2015","journal-title":"Circulation"},{"key":"2022031211205977700_B54","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","article-title":"Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials","volume":"373","author":"Ray","year":"2009","journal-title":"Lancet"},{"key":"2022031211205977700_B55","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1007\/s00125-009-1470-0","article-title":"Intensive glucose control and macrovascular outcomes in type 2 diabetes","volume":"52","author":"Turnbull","year":"2009","journal-title":"Diabetologia"},{"key":"2022031211205977700_B56","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(15)00044-3","article-title":"Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials","volume":"3","author":"Udell","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031211205977700_B57","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1161\/CIRCULATIONAHA.118.035759","article-title":"Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control","volume":"138","author":"Inzucchi","year":"2018","journal-title":"Circulation"},{"key":"2022031211205977700_B58","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2022031211205977700_B59","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME Trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031211205977700_B60","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2337\/dc18-2207","article-title":"Ambulatory blood pressure reduction with SGLT-2 inhibitors: dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide","volume":"42","author":"Georgianos","year":"2019","journal-title":"Diabetes Care"},{"key":"2022031211205977700_B61","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","article-title":"Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials","volume":"136","author":"Lytvyn","year":"2017","journal-title":"Circulation"},{"key":"2022031211205977700_B62","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"2022031211205977700_B63","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1161\/CIRCULATIONAHA.119.040514","article-title":"The serendipitous story of SGLT2 inhibitors in heart failure","volume":"139","author":"Verma","year":"2019","journal-title":"Circulation"},{"key":"2022031211205977700_B64","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease","volume":"141","author":"Mazer","year":"2020","journal-title":"Circulation"},{"key":"2022031211205977700_B65","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1161\/CIRCULATIONAHA.119.040057","article-title":"Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes mellitus","volume":"139","author":"Figtree","year":"2019","journal-title":"Circulation"},{"key":"2022031211205977700_B66","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus","volume":"139","author":"Kato","year":"2019","journal-title":"Circulation"},{"key":"2022031211205977700_B67","doi-asserted-by":"crossref","DOI":"10.2337\/db19-244-OR","article-title":"Effects of dapagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes: a predefined analysis from the DECLARE-TIMI 58 randomised, placebo-controlled trial","author":"Raz","year":"2019"},{"key":"2022031211205977700_B68","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/S2213-8587(17)30182-1","article-title":"Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial","volume":"5","author":"Cherney","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031211205977700_B69","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031211205977700_B70","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031211205977700_B71","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation"},{"key":"2022031211205977700_B72","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"2022031211205977700_B73","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.118.035901","article-title":"Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function","volume":"138","author":"Neuen","year":"2018","journal-title":"Circulation"},{"key":"2022031211205977700_B74","unstructured":"AstraZeneca\n          . Farxiga phase III DAPA-CKD trial will be stopped early after overwhelming efficacy in patients with chronic kidney disease. Accessed 28 April 2020. Available from https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2020\/farxiga-phase-iii-dapa-ckd-trial-will-be-stopped-early-after-overwhelming-efficacy-in-patients-with-chronic-kidney-disease.html"},{"key":"2022031211205977700_B75","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.kint.2019.02.033","article-title":"Analysis from the EMPA-REG OUTCOME\u00ae trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics","volume":"96","author":"Mayer","year":"2019","journal-title":"Kidney Int"},{"key":"2022031211205977700_B76","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/dom.13579","article-title":"Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers","volume":"21","author":"Heerspink","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2022031211205977700_B77","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.2337\/dc12-2572","article-title":"Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function","volume":"36","author":"Ekinci","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031211205977700_B78","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s001250050616","article-title":"Patterns of renal injury in NIDDM patients with microalbuminuria","volume":"39","author":"Fioretto","year":"1996","journal-title":"Diabetologia"},{"key":"2022031211205977700_B79","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031211205977700_B80","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031211205977700_B81","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S2213-8587(18)30023-8","article-title":"Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial","volume":"6","author":"Ludvik","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031211205977700_B82","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","article-title":"Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial","volume":"4","author":"Fr\u00edas","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031211205977700_B83","unstructured":"U.S. Food and Drug Administration\n          . Approval letter. Accessed 28 April 2020. Available from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/204042Orig1s032Approv.pdf"},{"key":"2022031211205977700_B84","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11892-018-1035-z","article-title":"Should metformin remain first-line medical therapy for patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease? An alternative approach","volume":"18","author":"Harrington","year":"2018","journal-title":"Curr Diab Rep"},{"key":"2022031211205977700_B85","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.2337\/dc20-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes\u20142020","volume":"43","author":"American Diabetes Association","year":"2020","journal-title":"Diabetes Care"},{"key":"2022031211205977700_B86","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1161\/CIR.0000000000000920","article-title":"Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association","volume":"142","author":"Rangaswami","year":"2020","journal-title":"Circulation"},{"key":"2022031211205977700_B87","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"2022031211205977700_B88","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.kint.2020.06.024","article-title":"Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment","volume":"98","author":"de Boer","year":"2020","journal-title":"Kidney Int"},{"key":"2022031211205977700_B89","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/jdi.12401","article-title":"Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors","volume":"7","author":"Ogawa","year":"2016","journal-title":"J Diabetes Investig"},{"key":"2022031211205977700_B90","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031211205977700_B91","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/dom.13611","article-title":"A safety update on sodium glucose co-transporter 2 inhibitors","volume":"21","author":"Fitchett","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2022031211205977700_B92","doi-asserted-by":"crossref","first-page":"1224-P","DOI":"10.2337\/db19-1224-P","article-title":"1224-P: Improving compliance with SGLT2 inhibitors by reducing the risk of genital mycotic infections: the outcomes of personal hygiene advice","volume":"68","author":"Williams","year":"2019","journal-title":"Diabetes"},{"key":"2022031211205977700_B93","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1001\/jamainternmed.2019.2813","article-title":"Association of sodium-glucose cotransporter 2 inhibitor treatment with risk of hospitalization for Fournier gangrene among men","volume":"179","author":"Dave","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2022031211205977700_B94","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2337\/dc19-0653","article-title":"Trends in rates of infections requiring hospitalization among adults with versus without diabetes in the U.S., 2000-2015","volume":"43","author":"Harding","year":"2020","journal-title":"Diabetes Care"},{"key":"2022031211205977700_B95","doi-asserted-by":"crossref","first-page":"e022577","DOI":"10.1136\/bmjopen-2018-022577","article-title":"Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis","volume":"9","author":"Donnan","year":"2019","journal-title":"BMJ Open"},{"key":"2022031211205977700_B96","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1681\/ASN.2018100971","article-title":"Trends in angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use among those with impaired kidney function in the United States","volume":"30","author":"Murphy","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2022031211205977700_B97","doi-asserted-by":"crossref","first-page":"e1918169","DOI":"10.1001\/jamanetworkopen.2019.18169","article-title":"Clinical characteristics of and risk factors for chronic kidney disease among adults and children: an analysis of the CURE-CKD Registry","volume":"2","author":"Tuttle","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2022031211205977700_B98","doi-asserted-by":"crossref","first-page":"964","DOI":"10.2215\/CJN.11961115","article-title":"The See Kidney Disease targeted screening program for CKD","volume":"11","author":"Galbraith","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022031211205977700_B99","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/ndt\/gfs567","article-title":"Is albuminuria screening and treatment optimal in patients with type 2 diabetes in primary care? Observational data of the GIANTT cohort","volume":"28","author":"Hellemons","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2022031211205977700_B100","unstructured":"National Kidney Foundation\n          . NKF and CVS Kidney Care have joined forces to promote kidney health. Accessed 28 April 2020. Available from https:\/\/www.kidney.org\/news\/nkf-and-cvs-kidney-care-have-joined-forces-to-promote-kidney-health"},{"key":"2022031211205977700_B101","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/dme.14076","article-title":"Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial","volume":"36","author":"Kansal","year":"2019","journal-title":"Diabet Med"},{"key":"2022031211205977700_B102","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1001\/jama.2016.11237","article-title":"The high cost of prescription drugs in the United States: origins and prospects for reform","volume":"316","author":"Kesselheim","year":"2016","journal-title":"JAMA"},{"key":"2022031211205977700_B103","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1161\/CIRCULATIONAHA.116.024764","article-title":"Use of sodium glucose cotransporter 2 inhibitors in the hands of cardiologists: with great power comes great responsibility","volume":"134","author":"Cherney","year":"2016","journal-title":"Circulation"},{"key":"2022031211205977700_B104","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/CIRCULATIONAHA.117.022680","article-title":"Are we ready to bell the cat? A call for cardiologists to embrace glucose-lowering therapies proven to improve cardiovascular outcomes","volume":"138","author":"Nassif","year":"2018","journal-title":"Circulation"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/70\/1\/1\/438486\/dbi200040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/70\/1\/1\/438486\/dbi200040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:41:01Z","timestamp":1667407261000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/70\/1\/1\/17901\/SGLT2-Inhibition-for-CKD-and-Cardiovascular"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,26]]},"references-count":104,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,10,26]]},"published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dbi20-0040","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,26]]}}}